S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN‐LABEL SOLACE‐KIDS TRIAL

Saved in:
Bibliographic Details
Published in:HemaSphere 2022-01, Vol.6 (Suppl), p.12-12
Main Authors: Heeney, M, Rees, D, Montalembert, M, Odame, I, Brown, C, Wali, Y, Nguyen, T, Lam, D, Pfender, N, Kanter, J
Format: Article
Language:English
Subjects:
Clinical and Epidemiological Studies
Oral Presentations
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3863-3dd0261ca8a003eca2cf65c74b87d92d780b535d898f7a6154731a620c749dea3
cites
container_end_page 12
container_issue Suppl
container_start_page 12
container_title HemaSphere
container_volume 6
creator Heeney, M
Rees, D
Montalembert, M
Odame, I
Brown, C
Wali, Y
Nguyen, T
Lam, D
Pfender, N
Kanter, J
description
doi_str_mv 10.1097/01.HS9.0000821456.11824.0b
format article
fullrecord <record><control><sourceid>wiley_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_49f5091b2b314cedb427cb18f05faf4a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_49f5091b2b314cedb427cb18f05faf4a</doaj_id><sourcerecordid>HEM3BF03255</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3863-3dd0261ca8a003eca2cf65c74b87d92d780b535d898f7a6154731a620c749dea3</originalsourceid><addsrcrecordid>eNqVks1u1DAUhSMEElXpO1isQGqm_suPZ4HkZhxiNTOpxhmhdmM5idOZkjZVMqXqjkfgLXgvngRPpwK6xBvfe33O57s4nvcewQmCLDqBaJIpNoHuxBjRIJwgFGM6gdUr7wAHEfYZpuj1P_Vb72gcr50eMcZCHB14PxXCeAoUT0V5AfhiBkSayoQnF6BIQbKUl3yRy8vVnJ8CuQB8VuRCJWJRKvBFlhlQMjnLBUhEnoOZVIIrAT6oZPZx6uSylNyNeclBuizmoMwEOM92EimPwXyVl3KHEstjUJyLxa_vP3J-KnKgipwnwrVncqZAuXSUd96b1nSjPXq-D72V2zjJ_Lz47NbN_ZrEIfFJ00AcotrEBkJia4PrNgzqiFZx1DDcRDGsAhI0MYvbyIQooBFBJsTQSVhjDTn05J7b9OZa3w2bGzM86t5s9NOgH660GbaburOasjaADFW4IojWtqkojuoKxS0MWtPSHevTnnV3X93Ypra328F0L6AvX243a33Vf9NxjDCMoANM94B66MdxsO0fL4J6FwENkXYR0H8joJ8ioGHlzHRvfui7rR3Gr939gx302ppuu9YQQ0QpYj6G2JUuEb5jYOJsybNt09nH__hQZ2JOTlNIcBCQ39SVvM4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN‐LABEL SOLACE‐KIDS TRIAL</title><source>Open Access: PubMed Central</source><source>Open Access: Wiley-Blackwell Open Access Journals</source><creator>Heeney, M ; Rees, D ; Montalembert, M ; Odame, I ; Brown, C ; Wali, Y ; Nguyen, T ; Lam, D ; Pfender, N ; Kanter, J</creator><creatorcontrib>Heeney, M ; Rees, D ; Montalembert, M ; Odame, I ; Brown, C ; Wali, Y ; Nguyen, T ; Lam, D ; Pfender, N ; Kanter, J</creatorcontrib><identifier>ISSN: 2572-9241</identifier><identifier>EISSN: 2572-9241</identifier><identifier>DOI: 10.1097/01.HS9.0000821456.11824.0b</identifier><language>eng</language><publisher>Philadelphia, PA: Lippincott Williams &amp; Wilkins</publisher><subject>Clinical and Epidemiological Studies ; Oral Presentations</subject><ispartof>HemaSphere, 2022-01, Vol.6 (Suppl), p.12-12</ispartof><rights>Copyright © 2022 The Author(s).</rights><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3863-3dd0261ca8a003eca2cf65c74b87d92d780b535d898f7a6154731a620c749dea3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812070/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812070/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11561,27923,27924,46051,46475,53790,53792</link.rule.ids></links><search><creatorcontrib>Heeney, M</creatorcontrib><creatorcontrib>Rees, D</creatorcontrib><creatorcontrib>Montalembert, M</creatorcontrib><creatorcontrib>Odame, I</creatorcontrib><creatorcontrib>Brown, C</creatorcontrib><creatorcontrib>Wali, Y</creatorcontrib><creatorcontrib>Nguyen, T</creatorcontrib><creatorcontrib>Lam, D</creatorcontrib><creatorcontrib>Pfender, N</creatorcontrib><creatorcontrib>Kanter, J</creatorcontrib><title>S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN‐LABEL SOLACE‐KIDS TRIAL</title><title>HemaSphere</title><subject>Clinical and Epidemiological Studies</subject><subject>Oral Presentations</subject><issn>2572-9241</issn><issn>2572-9241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>DOA</sourceid><recordid>eNqVks1u1DAUhSMEElXpO1isQGqm_suPZ4HkZhxiNTOpxhmhdmM5idOZkjZVMqXqjkfgLXgvngRPpwK6xBvfe33O57s4nvcewQmCLDqBaJIpNoHuxBjRIJwgFGM6gdUr7wAHEfYZpuj1P_Vb72gcr50eMcZCHB14PxXCeAoUT0V5AfhiBkSayoQnF6BIQbKUl3yRy8vVnJ8CuQB8VuRCJWJRKvBFlhlQMjnLBUhEnoOZVIIrAT6oZPZx6uSylNyNeclBuizmoMwEOM92EimPwXyVl3KHEstjUJyLxa_vP3J-KnKgipwnwrVncqZAuXSUd96b1nSjPXq-D72V2zjJ_Lz47NbN_ZrEIfFJ00AcotrEBkJia4PrNgzqiFZx1DDcRDGsAhI0MYvbyIQooBFBJsTQSVhjDTn05J7b9OZa3w2bGzM86t5s9NOgH660GbaburOasjaADFW4IojWtqkojuoKxS0MWtPSHevTnnV3X93Ypra328F0L6AvX243a33Vf9NxjDCMoANM94B66MdxsO0fL4J6FwENkXYR0H8joJ8ioGHlzHRvfui7rR3Gr939gx302ppuu9YQQ0QpYj6G2JUuEb5jYOJsybNt09nH__hQZ2JOTlNIcBCQ39SVvM4</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Heeney, M</creator><creator>Rees, D</creator><creator>Montalembert, M</creator><creator>Odame, I</creator><creator>Brown, C</creator><creator>Wali, Y</creator><creator>Nguyen, T</creator><creator>Lam, D</creator><creator>Pfender, N</creator><creator>Kanter, J</creator><general>Lippincott Williams &amp; Wilkins</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202201</creationdate><title>S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN‐LABEL SOLACE‐KIDS TRIAL</title><author>Heeney, M ; Rees, D ; Montalembert, M ; Odame, I ; Brown, C ; Wali, Y ; Nguyen, T ; Lam, D ; Pfender, N ; Kanter, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3863-3dd0261ca8a003eca2cf65c74b87d92d780b535d898f7a6154731a620c749dea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Clinical and Epidemiological Studies</topic><topic>Oral Presentations</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heeney, M</creatorcontrib><creatorcontrib>Rees, D</creatorcontrib><creatorcontrib>Montalembert, M</creatorcontrib><creatorcontrib>Odame, I</creatorcontrib><creatorcontrib>Brown, C</creatorcontrib><creatorcontrib>Wali, Y</creatorcontrib><creatorcontrib>Nguyen, T</creatorcontrib><creatorcontrib>Lam, D</creatorcontrib><creatorcontrib>Pfender, N</creatorcontrib><creatorcontrib>Kanter, J</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley Free Archive</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>HemaSphere</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heeney, M</au><au>Rees, D</au><au>Montalembert, M</au><au>Odame, I</au><au>Brown, C</au><au>Wali, Y</au><au>Nguyen, T</au><au>Lam, D</au><au>Pfender, N</au><au>Kanter, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN‐LABEL SOLACE‐KIDS TRIAL</atitle><jtitle>HemaSphere</jtitle><date>2022-01</date><risdate>2022</risdate><volume>6</volume><issue>Suppl</issue><spage>12</spage><epage>12</epage><pages>12-12</pages><issn>2572-9241</issn><eissn>2572-9241</eissn><cop>Philadelphia, PA</cop><pub>Lippincott Williams &amp; Wilkins</pub><doi>10.1097/01.HS9.0000821456.11824.0b</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2572-9241
ispartof HemaSphere, 2022-01, Vol.6 (Suppl), p.12-12
issn 2572-9241
2572-9241
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_49f5091b2b314cedb427cb18f05faf4a
source Open Access: PubMed Central; Open Access: Wiley-Blackwell Open Access Journals
subjects Clinical and Epidemiological Studies
Oral Presentations
title S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN‐LABEL SOLACE‐KIDS TRIAL
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T13%3A42%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=S122:%20SAFETY%20AND%20EFFICACY%20OF%20CRIZANLIZUMAB%20IN%20ADOLESCENTS%20WITH%20SICKLE%20CELL%20DISEASE%20(SCD):%20INITIAL%20DATA%20FROM%20THE%20PHASE%20II,%20MULTICENTER,%20OPEN%E2%80%90LABEL%20SOLACE%E2%80%90KIDS%20TRIAL&rft.jtitle=HemaSphere&rft.au=Heeney,%20M&rft.date=2022-01&rft.volume=6&rft.issue=Suppl&rft.spage=12&rft.epage=12&rft.pages=12-12&rft.issn=2572-9241&rft.eissn=2572-9241&rft_id=info:doi/10.1097/01.HS9.0000821456.11824.0b&rft_dat=%3Cwiley_doaj_%3EHEM3BF03255%3C/wiley_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3863-3dd0261ca8a003eca2cf65c74b87d92d780b535d898f7a6154731a620c749dea3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true